Ischemic StrokeWILLNCT07592962
Whole-life Investigation of Lishui Longevity
An observational study of Ischemic Stroke and Chronic Disease, run by The Fifth Affiliated Hospital of Wenzhou Medical University & Lishui Central Hospital at 1 site in China.
Trial summary
1. To establish a standardized, normalized and scientific joint screening and follow-up management system for chronic disease multimorbidity in Lishui City, and early identify common risk factors of major chronic diseases such as cardiovascular and cerebrovascular diseases and tumors. 2. Read more about this study
- Who is it for?
- Ages 30 to 80 years
- Conditions the study is for
- Ischemic Stroke, Chronic Disease, Cardiovascular
- How many people
- 4,500 participants
- Where
- 1 siteChina
- Study dates
- 18 May 2026to 31 May 2036
- How long will I take part?
- 10 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 30 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The study population consists of 4,500 participants aged 30-80 years recruited from 10 urban and 10 rural sites in Lishui City using a cluster sampling method. Participants are randomly divided into three equal groups of 1,500 each, receiving different examination protocols. The collected data are further analyzed and grouped into cerebrovascular, tumor, and epigenetic age categories based on the respective test results.
Who may be able to join
- Aged 30 to 80 years old; male-to-female ratio of 1:1; permanent residents in Lishui City; physically healthy; voluntary participation in the project with signed informed consent.
Who cannot join
- Individuals ever diagnosed with malignant tumors or cardiovascular and cerebrovascular diseases by physicians or other health professionals; those with unstable vital signs or an expected survival time of less than 3 months; participants with incomplete basic information, and those unable to cooperate with subsequent follow-up.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
Lishui Central Hospital
Lishui, Zhejiang, 323000
Jingping Sun, PhD, 86-18504713450, lszxyysunjingping@yeah.net
About this study
Official title: Whole-life Investigation of Lishui Longevity Cohort Study
- To establish a standardized, normalized and scientific joint screening and follow-up management system for chronic disease multimorbidity in Lishui City, and early identify common risk factors of major chronic diseases such as cardiovascular and cerebrovascular diseases and tumors.
- To carry out targeted intervention and long-term follow-up for high-risk populations, reduce the incidence risk of major chronic diseases in the target population, improve residents' health status and grassroots comprehensive prevention and treatment capacity of chronic diseases, and provide scientific evidence and practical support for the construction of Healthy Lishui.
Read the detailed description
This project will establish a cohort related to stroke and tumors, with 4500 subjects selected from the 30-80-year-old urban-rural integrated population in Lishui City, covering both urban and rural residents in the urban-rural junction area of the region. This population, with diverse living habits and uneven access to medical resources, is a key group for the prevention and control of stroke and tumors, and its selection can reflect the epidemiological characteristics of the two diseases in Lishui.
To achieve the research goal, the subjects will be randomly divided into three groups for targeted detection, with specific schemes as follows:
Group A: Magnetic Resonance (MR) examination (focusing on the head and neck to identify cerebrovascular and tissue abnormalities) and methylation pan-cancer detection (non-invasive and high-sensitivity, used to screen for early methylation abnormal changes of tumor-related genes).
Group B: Methylation pan-cancer detection (consistent with Group A), Transcranial Doppler (TCD) examination (for intracranial hemodynamic monitoring), cervical ultrasound (for assessing cervical artery conditions), and Vibration-Controlled Transient Elastography (VCTE) examination (for detecting liver elasticity).
Group C: Physiological age methylation detection (evaluating the real physiological aging state through the methylation level of age-related CpG sites) and VCTE examination (consistent with Group B) to supplement liver function-related detection.
The core purpose of this project is to explore the three-dimensional distribution (time, place, and population distribution) of stroke and tumors in this population. Time distribution aims to explore the variation rules of incidence rates across different seasons, years, and age stages; regional distribution aims to analyze the differences in incidence rates among different urban-rural junctions and their correlation with environmental and medical resource factors; population distribution aims to identify high-risk groups by analyzing the differences in incidence rates among different genders, ages, living habits, and physiological aging states.
In addition, this project will clarify the correlation between each detection indicator and the two diseases, improve the construction of biological sample banks and databases, provide a scientific basis for establishing a community-hospital linked intervention system, thereby improving the early detection rate and intervention rate of diseases and protecting the health of residents
- Conditions
- Ischemic Stroke, Chronic Disease, Cardiovascular
- Keywords
- acute ischemic stroke, carotid artery stenosis, Hepatic fibrosis
- Medical subject headings
- Ischemic Stroke, Chronic Disease, Carotid Stenosis, Liver Cirrhosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Cerebrovascular group | Participants in the cerebrovascular group receive head and neck magnetic resonance (MR) examination, transcranial Doppler (TCD) and cervical ultrasound. These examinations are used to screen cerebrovascular structural lesions, intracranial hemodynamic disorders and cervical atherosclerotic plaques, so as to identify early risk factors for stroke and cerebrovascular diseases. | |
| Tumor Group | The tumor group undergoes methylation pan-cancer detection. This non-invasive and high-sensitivity assay is applied to screen aberrant methylation of tumor-related genes, covering ten common cancers including cervical cancer, esophageal cancer, lung squamous cell carcinoma, prostate cancer, liver cancer, lung adenocarcinoma, colon cancer, rectal cancer, gastric cancer and pancreatic cancer, enabling early identification of potential malignant tumor risk in the population. | |
| Epigenetic Age Group | The epigenetic age group accepts physiological age methylation detection combined with Vibration-Controlled Transient Elastography (VCTE). Methylation profiling of age-related CpG sites is used to evaluate individual physiological aging status, while VCTE is supplemented to assess liver elasticity and related metabolic characteristics. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Prevalence rate of stroke and tumors
A blood-based methylation pan-cancer assay was performed to screen for ten common malignancies, including cervical cancer, esophageal cancer, lung squamous cell carcinoma, prostate cancer, liver cancer, lung adenocarcinoma, colon cancer, rectal cancer, gastric cancer, and pancreatic cancer. The prevalence of each cancer type was calculated as the number of confirmed positive cases divided by the total number of participants screened.
Measured: From enrollment to the end of the 10-year follow-up period
Secondary outcomes (1)
Unilateral carotid artery stenosis rate
The degree of cervical vascular stenosis was detected and evaluated. The distribution of unilateral carotid artery stenosis rate (defined as stenosis degree >50%) was analyzed, which was calculated as the number of participants with carotid stenosis greater than 50% divided by the total screened population.
Measured: From enrollment to the end of the 10-year follow-up period
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 May 2026
- Study start18 May 2026 (estimated)
- Primary completion31 May 2036 (estimated)
- Study completion31 May 2036 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (15)Papers the sponsor has linked to this study.
- Other trials for Ischemic StrokeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 4,500 participants (estimated)
- Target duration
- 10 Years
Sponsor and investigators
- Lead sponsor
- The Fifth Affiliated Hospital of Wenzhou Medical University & Lishui Central Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Jiansong Ji, PhD, Study chair, The Central Hospital of Lishui City
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07592962
- Sponsor's protocol ID
- 2026(I)164-01
- Other IDs
- Lishui Key R&D Project
- Acronym
- WILL
- Status last verified
- May 2026
- First submitted
- 12 May 2026
- Last updated
- 18 May 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: The individual participant data (IPD) for this study will not be shared publicly due to concerns regarding participant privacy, data security, and the lack of an established data sharing agreement and platform. All data are stored and managed in accordance with applicable data protection regulations and institutional policies.
Publications
Pacinella G, Bona MM, Todaro F, Ciaccio AM, Daidone M, Tuttolomondo A. Tracing Inflammation in Ischemic Stroke: Biomarkers and Clinical Insight. Int J Mol Sci. 2025 Oct 8;26(19):9801. doi: 10.3390/ijms26199801.
PubMed 41097065Wang J, Li Y, Qi L, Mamtilahun M, Liu C, Liu Z, Shi R, Wu S, Yang GY. Advanced rehabilitation in ischaemic stroke research. Stroke Vasc Neurol. 2024 Aug 27;9(4):328-343. doi: 10.1136/svn-2022-002285.
PubMed 37788912Tao T, Liu M, Chen M, Luo Y, Wang C, Xu T, Jiang Y, Guo Y, Zhang JH. Natural medicine in neuroprotection for ischemic stroke: Challenges and prospective. Pharmacol Ther. 2020 Dec;216:107695. doi: 10.1016/j.pharmthera.2020.107695. Epub 2020 Sep 28.
PubMed 32998014Zhao D, Guallar E, Qiao Y, Knopman DS, Palatino M, Gottesman RF, Mosley TH Jr, Wasserman BA. Intracranial Atherosclerotic Disease and Incident Dementia: The ARIC Study (Atherosclerosis Risk in Communities). Circulation. 2024 Sep 10;150(11):838-847. doi: 10.1161/CIRCULATIONAHA.123.067003. Epub 2024 Aug 1.
PubMed 39087353Gilbertson RJ. Mapping cancer origins. Cell. 2011 Apr 1;145(1):25-9. doi: 10.1016/j.cell.2011.03.019.
PubMed 21458665Paleari L. Personalized Assessment for Cancer Prevention, Detection, and Treatment. Int J Mol Sci. 2024 Jul 26;25(15):8140. doi: 10.3390/ijms25158140.
PubMed 39125710Torre LA, Siegel RL, Ward EM, Jemal A. Global Cancer Incidence and Mortality Rates and Trends--An Update. Cancer Epidemiol Biomarkers Prev. 2016 Jan;25(1):16-27. doi: 10.1158/1055-9965.EPI-15-0578. Epub 2015 Dec 14.
PubMed 26667886Wang W, Jiang B, Sun H, Ru X, Sun D, Wang L, Wang L, Jiang Y, Li Y, Wang Y, Chen Z, Wu S, Zhang Y, Wang D, Wang Y, Feigin VL; NESS-China Investigators. Prevalence, Incidence, and Mortality of Stroke in China: Results from a Nationwide Population-Based Survey of 480 687 Adults. Circulation. 2017 Feb 21;135(8):759-771. doi: 10.1161/CIRCULATIONAHA.116.025250. Epub 2017 Jan 4.
PubMed 28052979Hachinski V, Einhaupl K, Ganten D, Alladi S, Brayne C, Stephan BCM, Sweeney MD, Zlokovic B, Iturria-Medina Y, Iadecola C, Nishimura N, Schaffer CB, Whitehead SN, Black SE, Ostergaard L, Wardlaw J, Greenberg S, Friberg L, Norrving B, Rowe B, Joanette Y, Hacke W, Kuller L, Dichgans M, Endres M, Khachaturian ZS. Preventing dementia by preventing stroke: The Berlin Manifesto. Alzheimers Dement. 2019 Jul;15(7):961-984. doi: 10.1016/j.jalz.2019.06.001.
PubMed 31327392Levine DA, Galecki AT, Langa KM, Unverzagt FW, Kabeto MU, Giordani B, Wadley VG. Trajectory of Cognitive Decline After Incident Stroke. JAMA. 2015 Jul 7;314(1):41-51. doi: 10.1001/jama.2015.6968.
PubMed 26151265Lourida I, Hannon E, Littlejohns TJ, Langa KM, Hypponen E, Kuzma E, Llewellyn DJ. Association of Lifestyle and Genetic Risk With Incidence of Dementia. JAMA. 2019 Aug 6;322(5):430-437. doi: 10.1001/jama.2019.9879.
PubMed 31302669GBD 2016 Neurology Collaborators. Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019 May;18(5):459-480. doi: 10.1016/S1474-4422(18)30499-X. Epub 2019 Mar 14.
PubMed 30879893GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018 Nov 10;392(10159):1736-1788. doi: 10.1016/S0140-6736(18)32203-7. Epub 2018 Nov 8.
PubMed 30496103Zhao Y, Zhang X, Chen X, Wei Y. Neuronal injuries in cerebral infarction and ischemic stroke: From mechanisms to treatment (Review). Int J Mol Med. 2022 Feb;49(2):15. doi: 10.3892/ijmm.2021.5070. Epub 2021 Dec 8.
PubMed 34878154Pan Y, Jing J, Cai X, Wang Y, Wang S, Meng X, Zeng C, Shi J, Ji J, Lin J, Lyu L, Zhang Z, Mei L, Li S, Li S, Zhu W, Li H, Wei T, Wang Y. PolyvasculaR Evaluation for Cognitive Impairment and vaScular Events (PRECISE)-a population-based prospective cohort study: rationale, design and baseline participant characteristics. Stroke Vasc Neurol. 2021 Mar;6(1):145-151. doi: 10.1136/svn-2020-000411. Epub 2020 Aug 30.
PubMed 32863279
Study at a glance
From the registry record, last updated by the sponsor on 18 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Whole-life Investigation of Lishui Longevity Cohort Study
- ClinicalTrials.gov ID
- NCT07592962
- Acronym / sponsor ID
- WILL / 2026(I)164-01
- Conditions
- Ischemic Stroke, Chronic Disease, Cardiovascular
- Keywords
- acute ischemic stroke, carotid artery stenosis, Hepatic fibrosis
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 4,500 participants (estimated)
- Lead sponsor
- The Fifth Affiliated Hospital of Wenzhou Medical University & Lishui Central HospitalUniversity, hospital or other
- Study start
- 18 May 2026 (estimated)
- Primary completion
- 31 May 2036 (estimated)
- Study completion
- 31 May 2036 (estimated)
- First posted
- 18 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
- To establish a standardized, normalized and scientific joint screening and follow-up management system for chronic disease multimorbidity in Lishui City, and early identify common risk factors of major chronic diseases such as cardiovascular and cerebrovascular diseases and tumors.
- To carry out targeted intervention and long-term follow-up for high-risk populations, reduce the incidence risk of major chronic diseases in the target population, improve residents' health status and grassroots comprehensive prevention and treatment capacity of chronic diseases, and provide scientific evidence and practical support for the construction of Healthy Lishui.
Detailed description
This project will establish a cohort related to stroke and tumors, with 4500 subjects selected from the 30-80-year-old urban-rural integrated population in Lishui City, covering both urban and rural residents in the urban-rural junction area of the region. This population, with diverse living habits and uneven access to medical resources, is a key group for the prevention and control of stroke and tumors, and its selection can reflect the epidemiological characteristics of the two diseases in Lishui.
To achieve the research goal, the subjects will be randomly divided into three groups for targeted detection, with specific schemes as follows:
Group A: Magnetic Resonance (MR) examination (focusing on the head and neck to identify cerebrovascular and tissue abnormalities) and methylation pan-cancer detection (non-invasive and high-sensitivity, used to screen for early methylation abnormal changes of tumor-related genes).
Group B: Methylation pan-cancer detection (consistent with Group A), Transcranial Doppler (TCD) examination (for intracranial hemodynamic monitoring), cervical ultrasound (for assessing cervical artery conditions), and Vibration-Controlled Transient Elastography (VCTE) examination (for detecting liver elasticity).
Group C: Physiological age methylation detection (evaluating the real physiological aging state through the methylation level of age-related CpG sites) and VCTE examination (consistent with Group B) to supplement liver function-related detection.
The core purpose of this project is to explore the three-dimensional distribution (time, place, and population distribution) of stroke and tumors in this population. Time distribution aims to explore the variation rules of incidence rates across different seasons, years, and age stages; regional distribution aims to analyze the differences in incidence rates among different urban-rural junctions and their correlation with environmental and medical resource factors; population distribution aims to identify high-risk groups by analyzing the differences in incidence rates among different genders, ages, living habits, and physiological aging states.
In addition, this project will clarify the correlation between each detection indicator and the two diseases, improve the construction of biological sample banks and databases, provide a scientific basis for establishing a community-hospital linked intervention system, thereby improving the early detection rate and intervention rate of diseases and protecting the health of residents
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 10 Years
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Cerebrovascular group | – | –Participants in the cerebrovascular group receive head and neck magnetic resonance (MR) examination, transcranial Doppler (TCD) and cervical ultrasound. These examinations are used to screen cerebrovascular structural lesions, intracranial hemodynamic disorders and cervical atherosclerotic plaques, so as to identify early risk factors for stroke and cerebrovascular diseases. |
| Tumor Group | – | –The tumor group undergoes methylation pan-cancer detection. This non-invasive and high-sensitivity assay is applied to screen aberrant methylation of tumor-related genes, covering ten common cancers including cervical cancer, esophageal cancer, lung squamous cell carcinoma, prostate cancer, liver cancer, lung adenocarcinoma, colon cancer, rectal cancer, gastric cancer and pancreatic cancer, enabling early identification of potential malignant tumor risk in the population. |
| Epigenetic Age Group | – | –The epigenetic age group accepts physiological age methylation detection combined with Vibration-Controlled Transient Elastography (VCTE). Methylation profiling of age-related CpG sites is used to evaluate individual physiological aging status, while VCTE is supplemented to assess liver elasticity and related metabolic characteristics. |
Who may qualify
- Ages
- 30 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The study population consists of 4,500 participants aged 30-80 years recruited from 10 urban and 10 rural sites in Lishui City using a cluster sampling method. Participants are randomly divided into three equal groups of 1,500 each, receiving different examination protocols. The collected data are further analyzed and grouped into cerebrovascular, tumor, and epigenetic age categories based on the respective test results.
Key inclusion criteria (1 listed)
- Aged 30 to 80 years old; male-to-female ratio of 1:1; permanent residents in Lishui City; physically healthy; voluntary participation in the project with signed informed consent.
Key exclusion criteria (1 listed)
- Individuals ever diagnosed with malignant tumors or cardiovascular and cerebrovascular diseases by physicians or other health professionals; those with unstable vital signs or an expected survival time of less than 3 months; participants with incomplete basic information, and those unable to cooperate with subsequent follow-up.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Prevalence rate of stroke and tumors
Time frame: From enrollment to the end of the 10-year follow-up period
A blood-based methylation pan-cancer assay was performed to screen for ten common malignancies, including cervical cancer, esophageal cancer, lung squamous cell carcinoma, prostate cancer, liver cancer, lung adenocarcinoma, colon cancer, rectal cancer, gastric cancer, and pancreatic cancer. The prevalence of each cancer type was calculated as the number of confirmed positive cases divided by the total number of participants screened.
1 secondary outcome
Unilateral carotid artery stenosis rate
Time frame: From enrollment to the end of the 10-year follow-up period
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 May 2026.
- Background: PubMed 41097065Pacinella G, Bona MM, Todaro F, Ciaccio AM, Daidone M, Tuttolomondo A. Tracing Inflammation in Ischemic Stroke: Biomarkers and Clinical Insight. Int J Mol Sci. 2025 Oct 8;26(19):9801. doi: 10.3390/ijms26199801.
- Background: PubMed 37788912Wang J, Li Y, Qi L, Mamtilahun M, Liu C, Liu Z, Shi R, Wu S, Yang GY. Advanced rehabilitation in ischaemic stroke research. Stroke Vasc Neurol. 2024 Aug 27;9(4):328-343. doi: 10.1136/svn-2022-002285.
- Background: PubMed 32998014Tao T, Liu M, Chen M, Luo Y, Wang C, Xu T, Jiang Y, Guo Y, Zhang JH. Natural medicine in neuroprotection for ischemic stroke: Challenges and prospective. Pharmacol Ther. 2020 Dec;216:107695. doi: 10.1016/j.pharmthera.2020.107695. Epub 2020 Sep 28.
- Background: PubMed 39087353Zhao D, Guallar E, Qiao Y, Knopman DS, Palatino M, Gottesman RF, Mosley TH Jr, Wasserman BA. Intracranial Atherosclerotic Disease and Incident Dementia: The ARIC Study (Atherosclerosis Risk in Communities). Circulation. 2024 Sep 10;150(11):838-847. doi: 10.1161/CIRCULATIONAHA.123.067003. Epub 2024 Aug 1.
- Background: PubMed 21458665Gilbertson RJ. Mapping cancer origins. Cell. 2011 Apr 1;145(1):25-9. doi: 10.1016/j.cell.2011.03.019.
- Background: PubMed 39125710Paleari L. Personalized Assessment for Cancer Prevention, Detection, and Treatment. Int J Mol Sci. 2024 Jul 26;25(15):8140. doi: 10.3390/ijms25158140.
- Background: PubMed 26667886Torre LA, Siegel RL, Ward EM, Jemal A. Global Cancer Incidence and Mortality Rates and Trends--An Update. Cancer Epidemiol Biomarkers Prev. 2016 Jan;25(1):16-27. doi: 10.1158/1055-9965.EPI-15-0578. Epub 2015 Dec 14.
- Background: PubMed 28052979Wang W, Jiang B, Sun H, Ru X, Sun D, Wang L, Wang L, Jiang Y, Li Y, Wang Y, Chen Z, Wu S, Zhang Y, Wang D, Wang Y, Feigin VL; NESS-China Investigators. Prevalence, Incidence, and Mortality of Stroke in China: Results from a Nationwide Population-Based Survey of 480 687 Adults. Circulation. 2017 Feb 21;135(8):759-771. doi: 10.1161/CIRCULATIONAHA.116.025250. Epub 2017 Jan 4.
- Background: PubMed 31327392Hachinski V, Einhaupl K, Ganten D, Alladi S, Brayne C, Stephan BCM, Sweeney MD, Zlokovic B, Iturria-Medina Y, Iadecola C, Nishimura N, Schaffer CB, Whitehead SN, Black SE, Ostergaard L, Wardlaw J, Greenberg S, Friberg L, Norrving B, Rowe B, Joanette Y, Hacke W, Kuller L, Dichgans M, Endres M, Khachaturian ZS. Preventing dementia by preventing stroke: The Berlin Manifesto. Alzheimers Dement. 2019 Jul;15(7):961-984. doi: 10.1016/j.jalz.2019.06.001.
- Background: PubMed 26151265Levine DA, Galecki AT, Langa KM, Unverzagt FW, Kabeto MU, Giordani B, Wadley VG. Trajectory of Cognitive Decline After Incident Stroke. JAMA. 2015 Jul 7;314(1):41-51. doi: 10.1001/jama.2015.6968.
- Background: PubMed 31302669Lourida I, Hannon E, Littlejohns TJ, Langa KM, Hypponen E, Kuzma E, Llewellyn DJ. Association of Lifestyle and Genetic Risk With Incidence of Dementia. JAMA. 2019 Aug 6;322(5):430-437. doi: 10.1001/jama.2019.9879.
- Background: PubMed 30879893GBD 2016 Neurology Collaborators. Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019 May;18(5):459-480. doi: 10.1016/S1474-4422(18)30499-X. Epub 2019 Mar 14.
- Individual participant dataSharing planned: No. The individual participant data (IPD) for this study will not be shared publicly due to concerns regarding participant privacy, data security, and the lack of an established data sharing agreement and platform. All data are stored and managed in accordance with applicable data protection regulations and institutional policies.
Related trials for Ischemic Stroke
Not yet recruiting
Temporal Interference Stimulation for Upper-Limb Motor Recovery in Early Subacute Stroke
Acute Ischemic Stroke
RecruitingObservational study
ELATE Study: Evaluating Large-vessel Acute Thrombectomy in Extended Time Window
Acute Ichemic Stroke
Not yet recruiting
Selective Intra-Arterial Hypothermia After Endovascular Treatment for Acute Basilar Artery Occlusion
Acute Ischemic Stroke, Basilar Artery Occlusion
Active, not recruiting
Improving Visual Field Deficits With Noninvasive Brain Stimulation
Visual Field Defect, Peripheral, Stroke
Recruiting
Biomarkers of Paired VNS
Stroke, Ischemic
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Jiansong Ji, PhD study chair
The Central Hospital of Lishui City
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Ischemic Stroke and Chronic Disease, run by The Fifth Affiliated Hospital of Wenzhou Medical University & Lishui Central Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 18 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Jingping Sun, PhD (86-18504713450, lszxyysunjingping@yeah.net), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Prevalence rate of stroke and tumors (time frame: From enrollment to the end of the 10-year follow-up period). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07592962, which also lists 15 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 May 2026.